Boris Freidlin
Overview
Explore the profile of Boris Freidlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moseley A, LeBlanc M, Freidlin B, Shallis R, Zeidan A, Sallman D, et al.
Clin Trials
. 2025 Jan;
:17407745241304065.
PMID: 39815460
Background/aims: Randomized clinical trials often use stratification to ensure balance between arms. Analysis of primary endpoints of these trials typically uses a "stratified analysis," in which analyses are performed separately...
2.
Hu C, Freidlin B, Korn E
Unknown
. 2025 Jan;
1:e2400066.
PMID: 39758134
Purpose: A phase II/III trial is a type of phase III trial that has embedded in it an intermediate phase II go/no-go decision as to whether to continue the accrual...
3.
4.
Korn E, Allegra C, Freidlin B
J Clin Oncol
. 2024 Oct;
43(2):226-233.
PMID: 39467219
Phase III trials that randomly assign patients to a control treatment (C), an experimental treatment (A), or a combination treatment (AB) should be designed with the goal to recommend the...
5.
Freidlin B, Korn E
JCO Oncol Pract
. 2024 Jul;
20(12):1555-1558.
PMID: 38986031
In a randomized clinical trial, instead of allocating patients equally between the treatment arms, some trials in oncology assign a higher proportion of patients to receive the experimental treatment arm...
6.
Korn E, Freidlin B
Stat Med
. 2024 May;
43(16):3109-3123.
PMID: 38780538
When designing a randomized clinical trial to compare two treatments, the sample size required to have desired power with a specified type 1 error depends on the hypothesis testing procedure....
7.
Othus M, Freidlin B, Korn E
J Clin Oncol
. 2024 May;
42(31):3753-3760.
PMID: 38759123
New oncology therapies that extend patients' lives beyond initial expectations and improving later-line treatments can lead to complications in clinical trial design and conduct. In particular, for trials with event-based...
8.
9.
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
Zhao Y, Yuan Y, Korn E, Freidlin B
Clin Cancer Res
. 2023 Dec;
30(4):673-679.
PMID: 38048044
In recent years, there has been increased interest in incorporation of backfilling into dose-escalation clinical trials, which involves concurrently assigning patients to doses that have been previously cleared for safety...
10.
Foster J, Korn E, Freidlin B, Moscow J
JNCI Cancer Spectr
. 2023 Nov;
7(6).
PMID: 38001028
No abstract available.